In addition, with the aim of knowing if the complete loss of EPCAM occurs in other tumors of the LS spectrum, we evaluated MSH2 and EPCAM expressions in a large series of malignant neoplasms, premalignant lesions of GI and extra-GI origin, and benign neoplasms located in different organs from patients with lack of MSH2 expression, in which we were able to perform a complete germ-line analysis. The gene discussed is MSH2; the disease is cancer.